Hilary D. Marston is the Chief Medical Officer of the Food and Drug Administration.[1]
Hilary D. Marston | |
|---|---|
 Hilary D. Marston | |
| Alma mater | Yale College (BA) University of Pennsylvania (MD) Harvard University (MPH) [1] |
| Scientific career | |
| Fields | Pandemic preparedness, clinical trial innovation, regulatory policy, global health |
| Institutions | Food and Drug Administration |
Career
editMarston worked for McKinsey & Company and at the Bill & Melinda Gates Foundation as a program officer and special assistant. She then studied medicine at the Perelman School of Medicine and completed her residency in internal medicine and Global Health Equity at Brigham and Women's Hospital and earned her M.P.H. at the Harvard T.H. Chan School of Public Health.[2] In 2013, Marston joined National Institute of Allergy and Infectious Diseases (NIAID), as a medical officer and policy advisor for global health and pandemic preparedness.[3] At NIAID she was instrumental in developing and organizing U.S. responses to the Ebola and Zika outbreaks.[4]
In 2021, Marston joined the United States National Security Council as director for medical and biodefense preparedness. She then served as director for global COVID-19 response on the White House COVID-19 Response Team. In this role, she led the US government's work in global distribution of COVID-19 vaccines, including overseeing sharing from the domestic supply and large-scale vaccine purchases for international donation. [4]
In 2022, Marston joined the US Food and Drug Administration as Chief Medical Officer.[5] In this role she oversees the Office of the Chief Medical Officer which guides efforts to ensure timely review of combination products, incentive programs to promote interventions for rare diseases, and dedicated labeling for pediatric patients. She provides executive leadership, coordination, and oversight of FDA cross-cutting clinical and public health emergency-related regulatory policy matters, and public health preparedness and response activities on behalf of the Commissioner. [1]
Selected works
edit- Marston, Hilary D.; Dixon, Dennis M.; Knisely, Jane M.; Palmore, Tara N.; Fauci, Anthony S. (September 2016). "Antimicrobial Resistance". JAMA. 316 (11): 383–394. doi:10.1001/jama.2016.11764. ISSN 0098-7484. PMC 2536104. PMID 6603914.
- Paules, Catharine I.; Marston, Hilary D.; Eisinger, Robert W.; Baltimore, David; Fauci, Anthony S. (October 2017). "The Pathway to a Universal Influenza Vaccine". Immunity. 47 (4): 599–603. doi:10.1016/j.immuni.2017.09.007. ISSN 1074-7613. PMID 29045889.
- Paules, Catharine I.; Marston, Hilary D.; Fauci, Anthony S. (February 2020). "Coronavirus Infections—More Than Just the Common Cold". JAMA. 323 (8): 707–708. doi:10.1001/jama.2020.0757. ISSN 0098-7484. PMID 31971553.
- Warraich, HJ; Marston, HD; Califf, RM (8 February 2024). "Addressing the Challenge of Common Chronic Diseases - A View from the FDA". The New England journal of medicine. 390 (6): 490–492. doi:10.1056/NEJMp2313217. PMID 38314843.
References
edit- ^ a b c "Hilary Marston". Food and Drug Administration. 24 November 2024.
- ^ "Hilary Marston, M.D., M.P.H." (PDF). Retrieved 25 November 2024.
- ^ "Office of the Chief of Staff - Contacts". NIH: National Institute of Allergy and Infectious Diseases. Retrieved 2021-01-28.
This article incorporates text from this source, which is in the public domain.
- ^ a b "2021 Alumni Awards announced". Retrieved 24 November 2024.
- ^ "FDA adds some fresh senior leadership with new chief scientist, chief medical officer". Endpoints News. Retrieved 3 March 2023.
This article incorporates public domain material from websites or documents of the National Institutes of Health.